POST-MARKETING STUDY OF THE CLINICAL EFFICACY AND SAFETY OF GRIPMAX NOS IN THE TREATMENT OF ACUTE RESPIRATORY INFECTIONS OF THE UPPER RESPIRATORY TRACT
Background. The relevance of the study is due to the high prevalence of acute respiratory infections, which pose a significant threat to public health and require effective and safe treatment methods. A study of the efficacy and safety of Gripmax Nos as a monotherapy for such infections will help determine its potential to improve clinical outcomes and reduce the burden on the healthcare system.
The aim of the study: To retrospectively evaluate the efficacy and safety of monotherapy of acute respiratory infections with Gripmax Nos. in otolaryngological practice.
Material and research methods. The design of the study is a retrospective study. Patient data was recorded in time intervals from the moment of the first treatment and until the second visit, which was recorded after 30 days from the date of treatment. The data recording included the results of otolaryngological medical examinations. The final database of the study included 20 patients (12 female, 8 male) aged 8 to 64 years. Sensory-analog and visual-analog scales were used to assess the dynamics of clinical manifestations of the disease. To assess the results of treatment and tolerability, the IMOS scales were used – an Integral scale for evaluating treatment results (Integrative Medicine Outcome Scale) and IMPSS – an Integral scale for evaluating patient satisfaction with treatment (Integrative Medicine Patient Satisfaction Scale).
Results. According to the evaluation of the results of treatment according to the integral scale, 25% of patients were completely satisfied with the treatment, 63% were satisfied, 6% had a neutral attitude, 6% were not satisfied with the treatment. When evaluating the results of treatment, positive results were also obtained: complete recovery at the 2nd visit was noted in 19% of patients, significant improvement in 75% of patients, moderate improvement in 6% of patients. The analysis of subjective signs of the disease during treatment showed that already in the first 3-5 days of treatment there was a significant regression of the disease compared with the initial indicators of rhinoscopic parameters and clinical symptoms.
Conclusions. Thus, the use of Gripmax Nos in the otolaryngological practice of treating patients with acute rhinosinusitis makes it possible to achieve pronounced positive dynamics in the regression of symptoms during the first 3-5 days from the start of therapy. And also to increase its effectiveness at the beginning of therapy on the first day of the disease and the implementation of the principles of regimen and oral rehydration. Gripmax Nos is characterized by good tolerability in the treatment of patients with acute respiratory diseases.
Gulnara E. Ualiyeva, https://orcid.org/0009-0007-0015-0294
«City Clinical Hospital of Almaty»,
Almaty, Republic of Kazakhstan;
1. Бубенчикова В.Н., Старчак Ю.А. Изучение отхаркивающей активности растений рода тимьян // Медицинский вестник Башкортостана. 2013. Т.8, №5. С. 78–80;
2. Геппе Н.А., Соболева В.А., Суховьёва О.Г., Исаичкина Ю.В., Тихонова М.Н., Алиева Ю.С. Эффективность применения препарата Грипмакс® НОС детский при респираторной вирусной инфекции верхних дыхательных путей // Врач, 2024. Т. 35, №.1. C. 75-80. doi: 10.29296/25877305-2024-01-15
3. Романцова, Н.А., Шаталова Т.А. Разработка технологии сиропа отхаркивающего действия на основе фитокомплексов эвкалипта, душицы, чабреца // Разработка, исследование и маркетинг новой фармацевтической продукции: сборник научных трудов. Пятигорская государственная фармацевтическая академия, 2006. С. 127–129.
4. Akhtar N.M., Naseer R., Farooqi A.Z., Aziz W., Nazir M. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee-a double-blind prospective randomized study // Clinical Rheumatology, 2004, vol. 23, №5, pp. 410–415.
5. Baur X., Fruhmann G. Allergic reactions, including asthma, to the pineapple protease bromelain following occupational exposure // Clin. Allergy. 1979. Vol. 9, № 5. Р.443–450.
6. Bhattacharyya B.K. Bromelain: an overview // Natural Product Radiance, 2008. №4, vol. 7, pp. 359–363.
7. Bhui K., Prasad S., George J., Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF - kappa B against skin tumor-initiation triggering mitochondrial death pathway // Cancer Letters, 2009, vol. 282, №2, pp. 167–176.
8. Castell J.V., Friedrich G., Kuhn C.S., Poppe G.E. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake // American Journal of Physiology, 1997. Vol. 273, №1, pp. G139–G146.
9. Desser L., Rehberger A., Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro // Cancer Biotherapy, 1994; vol. 9, №3, pp. 253–263.
10. Desser L., Rehberger A., Kokron E., Paukovits W. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations // Oncology, 1993; vol. 50, no. 6, pp. 403–407.
11. Engwerda C.R., Andrew D., Ladhams A., Mynott T.L. Bromelain modulates T cell and B cell immune responses in vitro and in vivo // Cellular Immunology, 2001. vol. 210, no. 1, pp. 66–75.
12. Hale L.P., Haynes B.F. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation / Journal of Immunology, 1992. vol.149, №.12, pp. 3809–3816.
13. Jaric S., Mitrovic M., Pavlovic P. Review of ethnobotanical, phytochemical, and pharmacological study of Thymus serpyllum // Evid. Based Complement. Alternat. Med. – 2015. с 24-35
14. Rasooli I., Mirmostafa S.A. Antibacterial properties of Thymus pubescens and Thymus serpyllum essential oils - Fitoterapia. 2002, Jun., 73(3), 244–250;
15. Rasooli I., Mirmostafa S.A. 2200–2205. Bacterial susceptibility to and chemical composition of essential oils from Thymus kotschyanus and Thymus persicus // J. Agric. Food Chem. 2003, 51(8),с 2200-2005
16. Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis // Headache. 1967, vol 7, no.1, pp.13-7
17. SecorJr.E., Singh A., Guernsey L.A. et al. Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro // International Immunopharmacology, 2009, vol. 9, no. 3, pp. 340–346.
18. Secor E.R., William F.C., Michelle M.C. et al. Bromelain exerts anti-inammatory effects in an ovalbumin-induced murin model of allergic disease // in Cellular Immunology, 2005. vol. 237, pp. 68–75.
References: [1-2]
1. Bubenchikova V.N., Starchak Yu.A. Izuchenie otkharkivayushchey aktivnosti rasteniy roda timyan [Study of expectorant activity of thyme plants]. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2013. V.8. №5. pp. 78–80; [in Russian]
2. Geppe N.A., Soboleva V.A., Sukhov'eva O.G., Isaichkina Yu.V., Tikhonova M.N., Alieva Yu.S. Effektivnost' primeneniya preparata Gripmaks® NOS detskii pri respiratornoi virusnoi infektsii verkhnikh dykhatel'nykh putei [The effectiveness of the use of the drug Gripmax® NOS for children in respiratory viral infections of the upper respiratory tract]. Vrach [Doctor], 2024, V. 35, №.1, pp. 75-80. doi: 10.29296/25877305-2024-01-15 [in Russian]
3. Romantsova N.A., Shatalova T.A. Razrabotka tekhnologii siropa otkharkivayushchego deystviya na osnove fitokompleksov evkalipta, dushitsy, chabretsa [Development, research and marketing of new pharmaceutical products: collection of scientific papers]. Razrabotka, issledovanie i marketing novoy farmatsevticheskoy produktsii: sbornik nauchnykh trudov. Pyatigorskaya gosudarstvennaya farmatsevticheskaya akademiya. [Development, research and marketing of new pharmaceutical products: collection of scientific papers. Pyatigorsk State Pharmaceutical Academy]. 2006. pp. 127–129. [in Russian]
Number of Views: 313
Category of articles:
Original articles
Bibliography link
Ualiyeva G.E. Post-marketing study of the clinical efficacy and safety of GripMax Nos in the treatment of acute respiratory infections of the upper respiratory tract // Nauka i Zdravookhranenie [Science & Healthcare]. 2024, Vol.26 (2), pp. 89-96. doi 10.34689/SH.2024.26.2.012Related publications:
VALIDATION OF THE KAZAKH VERSION OF THE DEPRESSION ANXIETY STRESS SCALE (DASS-21) IN MEDICAL FACULTY STAFF SAMPLE: THE PILOT STUDY
PREDICTIVE VALUE OF PSYCHOMETRIC TESTING IN CONTEXT OF CREATING ADAPTIVE ENVIRONMENT FOR HIGHER MEDICAL EDUCATION
ASSESSMENT OF STUDENTS' AWARENESS ABOUT THE HARMS OF MICROPLASTICS ON THE HUMAN BODY
THE IMPACT OF COMPLAINTS ON QUALITY OF LIFE, PSYCHOLOGICAL WELL-BEING AND HEALTH OF MEDICAL WORKERS
DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE FOR PATIENTS "STUDYING THE OPINION OF PATIENTS' SATISFACTION WITH NURSE INDEPENDENT APPOINTMENT AT THE LEVEL OF PRIMARY HEALTH CARE"